Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
Gastroenterology Review
eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

High-dose amoxicillin and pantoprazole regimen for Helicobacter pylori eradication: a multi-center, multinational randomized controlled trial

Pezhman Alavinejad
1
,
Samira Mohamadi
1
,
Mohammad Javad Rezaei
,
Abazar Parsi
1
,
Ahmad Hormati
2
,
Eskandar Hajiani
1
,
Omid Eslami
3
,
Morteza Nayebi
4
,
Siamak Baghaei
1
,
Mohammed Hussien Ahmed
5
,
Quang Trung Tran
6
,
Azam Satari
1

  1. Alimentary Tract Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Shariati Hospital, Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. Kerman University of Medical Sciences, Kerman, Iran
  5. Iran University of Medical Sciences, Tehran, Iran
  6. Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Vietnam
Gastroenterology Rev
DOI: https://doi.org/10.5114/pg.2025.151887
Online publish date: 2025/06/09
Article file
- High-dose amoxicillin.pdf  [0.11 MB]
Get citation
 
PlumX metrics:
 
1. Thung I, Aramin H, Vavinskaya V, et al. the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33.
2. Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021; 22: 729-41.
3. Hooi JK, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153: 420-9.
4. Sonnenberg A. Epidemiology of Helicobacter pylori. Aliment Pharmacol Ther 2022; 55: S1-3.
5. Sayehmiri F, Darvishi Z, Sayehmiri K, et al. A systematic review and meta-analysis study to investigate the prevalence of Helicobacter pylori and the sensitivity of its diagnostic methods in Iran. Iran Red Crescent Med J 2014; 16: e12581.
6. Jaroń K, Pietrzak A, Daniluk J, et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterol Rev 2023; 18: 225-48.
7. Mladenova I. Clinical relevance of Helicobacter pylori infection. J Clin Med 2021; 10: 3473.
8. Majumdar D, Bebb J. Helicobacter pylori infection and peptic ulcers. Medicine 2019; 47: 292-300.
9. Malfertheiner P, Megraud F, O’morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence consensus report. Gut 2017; 66: 6-30.
10. Nishizawa T, Suzuki H, Suzuki M, et al. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutrition 2012; 51: 114-6.
11. Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018; 33: 37-56.
12. Ding SZ, Du YQ, Lu H, et al. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 edition). Gut 2022; 71: 238-53.
13. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212-39.
14. Zou Y, Qian X, Liu X, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter 2020; 25: e12714.
15. Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology 2021; 161: 495-507.
16. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol 2020; 18: 89-98.
17. Kim SJ, Chung JW, Woo HS, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: a prospective open-label randomized trial. World J Gastroenterol 2019; 25: 6790.
18. Chua BQ, Chong VW, Teng TZ, et al. Does technology-enhanced communication improve Helicobacter pylori eradication outcomes? A meta-analysis. Helicobacter 2022; 27: e12890.
19. Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-82.
20. Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2: 707-15.
21. Hajiani E, Alavinejad P, Avandi N, et al. Comparison of levofloxacin-based, 10-day sequential therapy with 14-day quadruple therapy for Helicobacter pylori eradication: a randomized clinical trial. Middle East J Dig Dis 2018; 10: 242.
22. Alavinejad P, Seiedian SS, Hajiani E, et al. Comparison of furazolidone versus clarithromycin for eradication of Helicobacter pylori infection: a randomized multicenter clinical trial. Afro-Egyptian J Infect Endemic Dis 2021; 11: 44-50.
23. Öztürk K, Kurt Ö, Çelebi G, et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020; 31: 234.
24. Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine 2019; 98: e14396.
25. Zhu YJ, Zhang Y, Wang TY, et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Ther Adv Gastroenterol 2020; 13: 1756284820937115.
26. Hu CT. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – a review of the strengths, weaknesses, and proposed solutions. Tzu-Chi Med J 2022; 34: 303.
27. Yin Z, Li J, Huang W, et al. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Turk J Gastroenterol 2022; 33: 454.
28. Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther 2016; 14: 577-85.
29. Kwack W, Lim Y, Lim C, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for Helicobacter pylori infection in Korea. Gastroenterol Res Pract 2016; 2016: 1648047.
30. Gao CP, Xiao X, Liu PX, et al. High-dose amoxicillin/esomeprazole dual therapy as a first-line therapy for Helicobacter pylori eradication. World Chin J Digestol 2018; 26: 353-9.
31. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015; 13: 895-905.
32. Guan JL, Hu YL, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy 2022; 42: 224-32.
33. Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole-and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother 2019; 74: 1718-24.
34. Kim YI, Lee JY, Kim CG, et al. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021; 21: 95.
35. Gao W, Ye H, Deng X, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: a retrospective, real-life study. Helicobacter 2020; 25: e12717.
36. Hu JL, Yang J, Zhou YB, et al. Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol 2017; 23: 275.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.